PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($0.93), $0.03 worse than the analyst estimate of ($0.90). Revenue for the quarter came in at $1.69 million versus the consensus estimate of $1.76 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.